Gene therapy trial offers hope for healing 'Butterfly Skin' wounds
NCT ID NCT04213261
Summary
This study is testing whether a new gene therapy called FCX-007 can help heal wounds in people with recessive dystrophic epidermolysis bullosa (RDEB), a painful and severe genetic condition that causes fragile, blistering skin. The therapy involves taking a patient's own skin cells, modifying them with a corrective gene, and injecting them back into specific wounds. The main goal is to see if these treated wounds heal better than untreated wounds over 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Dell Children's Medical Group
Austin, Texas, 78723, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Solutions Through Advanced Research, Inc.
Jacksonville, Florida, 32256, United States
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.